XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Drug Des Devel Ther. 2022 Jan 3;16:3-12. doi: 10.2147/DDDT.S339305. eCollection 2022.
Abiraterone acetate tablets (I)(N-AbA) is a novel tablet co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). This study aimed to compare the pharmacokinetics, bioequivalence, safety, and food effects of N-AbA with the reference ZYTIGA (R-AbA) in healthy Chinese male subjects.
This study was conducted in three parts. Part I was an open, dose-escalation trial conducted in 16 Chinese healthy males; Part II was a randomized, open-label, 2 × 4 crossover, single-dose bioequivalence trial conducted in 36 subjects; Part III was a randomized, 3 × 3 crossover trial conducted on 24 volunteers to investigate the effect of food on the pharmacokinetics of N-AbA.
The exposure (AUC) and maximum concentration (C) of abiraterone and excipient SNAC were linear in the range of 75-450 mg dose. The bioavailability of N-AbA 300 mg was equivalent to that of R-AbA 1000 mg. The drug exposure of prednisone and prednisolone was not affected by SNAC co-administration. The C of orally administered abiraterone as R-AbA in a modified fed state was 5.9 times and AUC was 4.3 times, respectively, higher than those in of orally administered abiraterone as N-AbA in a high-fat diet. The C and AUC of orally administered abiraterone as N-AbA on a high-fat diet were 2.2 times and 2 times, respectively, higher than those on a fasting state. All adverse events reported in the three parts of the study were grade 1 or 2, and no serious adverse events were reported.
These three Phase I trials showed that N-AbA and excipient SNAC had excellent linear pharmacokinetic characteristics. A single dose of N-AbA 300 mg was bioequivalent to R-AbA 1000 mg in healthy subjects under fasting conditions. Meanwhile, SNAC had no effect on the pharmacokinetics of prednisone and prednisolone. The effect of food on N-AbA was significantly lower than that on R-AbA.
醋酸阿比特龙片(I)(N-AbA)是一种新型片剂,与吸收增强剂 N-(8-[2-羟基苯甲酰]氨基)辛酸酯(SNAC)联合制成。本研究旨在比较健康中国男性受试者中 N-AbA 与参比制剂 ZYTIGA(R-AbA)的药代动力学、生物等效性、安全性和食物效应。
这项研究分为三个部分进行。第 I 部分是一项在 16 名中国健康男性中进行的开放、剂量递增试验;第 II 部分是一项在 36 名受试者中进行的随机、开放标签、2×4 交叉、单次剂量生物等效性试验;第 III 部分是一项在 24 名志愿者中进行的随机、3×3 交叉试验,以研究食物对 N-AbA 药代动力学的影响。
阿比特龙和赋形剂 SNAC 的暴露(AUC)和最大浓度(C)在 75-450mg 剂量范围内呈线性。N-AbA 300mg 的生物利用度与 R-AbA 1000mg 相当。SNAC 联合给药不影响泼尼松龙和泼尼松的药物暴露。在改良进食状态下,口服给予 R-AbA 的阿比特龙的 C 和 AUC 分别是口服给予 N-AbA 的阿比特龙的 5.9 倍和 4.3 倍。在高脂肪饮食下,口服给予 N-AbA 的阿比特龙的 C 和 AUC 分别是空腹状态下的 2.2 倍和 2 倍。研究的三个部分报告的所有不良事件均为 1 级或 2 级,无严重不良事件报告。
这三项 I 期试验表明,N-AbA 和赋形剂 SNAC 具有优异的线性药代动力学特征。在健康受试者空腹状态下,单次给予 N-AbA 300mg 与 R-AbA 1000mg 具有生物等效性。同时,SNAC 对泼尼松龙和泼尼松的药代动力学无影响。食物对 N-AbA 的影响明显低于对 R-AbA 的影响。